Zydus Lifesciences Q4 FY26 Results: Net Profit Climbs 9%, Revenue Surges 16% — Complete Breakdown

By Kaushik Brahmakshatriya

Published On 20 May 2026.

Zydus Lifesciences Q4 Results FY26

Zydus Lifesciences Limited (NSE: ZYDUSLIFE) delivered a strong finish to the financial year 2025–26, reporting its Q4 FY26 results on May 19, 2026. The pharma giant posted solid numbers across revenue, EBITDA, and net profit — all growing on a year-on-year basis — while also rewarding shareholders with a dividend and a ₹1,100 crore share buyback plan. Here is a complete breakdown of what happened, what the numbers mean, and what lies ahead for the company.

Q4 FY26 Key Financial Highlights

Zydus Lifesciences reported a 9% growth in consolidated net profit at ₹1,273 crore for Q4 FY26 compared to ₹1,171 crore in the same quarter last year. Revenue from operations jumped 16% year-on-year to ₹7,587 crore, up from ₹6,528 crore in Q4 FY25.

The company’s EBITDA grew 20% annually to ₹2,554 crore, against ₹2,126 crore in Q4 FY25. Operating profit margin also expanded to 33.66% compared to 32.56% on a yearly basis.

For the full year, Zydus Lifesciences reported total revenue from operations of ₹27,148 crore for FY26, an increase of 16.8% over the previous year. Consolidated net profit stood at ₹5,040 crore, while adjusted net profit rose 15% to ₹5,456 crore.

Q4 FY26 vs Q4 FY25 — Financial Comparison

Metric	Q4 FY26	Q4 FY25	YoY Change
Revenue from Operations	₹7,587 Crore	₹6,528 Crore	+16%
EBITDA	₹2,554 Crore	₹2,126 Crore	+20%
EBITDA Margin	33.66%	32.56%	+110 bps
Net Profit (Consolidated)	₹1,273 Crore	₹1,171 Crore	+8.7%
R&D Investment (Q4)	₹698 Crore	—	9.2% of Revenue

Segment-Wise Performance — Where Did the Growth Come From?

Zydus operates across multiple business verticals, and Q4 FY26 showed clear strength in international and consumer wellness segments.

India Formulations: The India formulations business posted 14% year-on-year revenue growth to ₹1,752.8 crore, contributing 24% to consolidated revenue. The branded formulations business outpaced the broader market, supported by strong growth in chronic therapies including cardiology, respiratory, and dermatology.

North America: The North America formulations segment reported revenues of ₹2,952.3 crore, down 6% annually but up 5% sequentially, contributing 40% to consolidated revenues. In US dollar terms, the business posted $323 million in constant currency. The company filed three ANDAs, received approvals for nine ANDAs, and launched six new products during the quarter.

International Markets: The international markets formulations business posted strong growth of 45% year-on-year to ₹804 crore, driven by demand across emerging markets and Europe.

Consumer Wellness: The consumer wellness business rose 61% year-on-year to ₹1,463.3 crore, aided by growth in skin and hair care brands and international operations.

MedTech & API: The API business registered revenues of ₹122 crore, down 6% YoY, accounting for 2% of consolidated revenues.

The MedTech business contributed ₹327.5 crore during the quarter.

Segment Revenue Breakdown — Q4 FY26

Business Segment	Revenue (Q4 FY26)	YoY Growth	% of Total Revenue
North America Formulations	₹2,952 Crore	-6% YoY / +5% QoQ	40%
India Formulations	₹1,752 Crore	+14% YoY	24%
Consumer Wellness	₹1,463 Crore	+61% YoY	~19%
International Markets	₹804 Crore	+45% YoY	11%
MedTech	₹327 Crore	—	~4%
API Business	₹122 Crore	-6% YoY	2%

New Product Launches & Pipeline — A Busy Quarter

Zydus did not slow down on innovation during Q4 FY26. The company launched Tishtha, the biosimilar of Nivolumab, and Anyra, India’s first indigenously developed biosimilar of Aflibercept. It also strengthened its presence in the obesity and diabetes therapy segment by launching semaglutide injections under the brands Semaglyn, Mashema, and Alterme, and entered into co-marketing partnerships with Lupin and Torrent Pharmaceuticals for semaglutiede products in India.

In the rare disease space, the company expanded its specialty portfolio in the US with the launch of Zycubo for Menkes disease.

Dividend & Share Buyback — Rewarding Shareholders

The board recommended a final dividend of ₹1 per equity share of face value ₹1 each for FY26, translating to a 100% dividend, subject to shareholder approval at the annual general meeting. The record date for the dividend has been fixed as July 24, 2026.

The board also approved a buyback of up to 95,65,217 equity shares at ₹1,150 per share, with the total buyback size not exceeding ₹1,100 crore. The buyback represents 0.95% of the paid-up equity share capital and will be conducted through the tender offer route.

Dividend & Buyback Details

Parameter	Details
Final Dividend	₹1 per share (100%)
Dividend Record Date	July 24, 2026
Dividend Payment Date	August 14, 2026 (approx.)
AGM Date	August 11, 2026
Buyback Price	₹1,150 per share
Total Buyback Size	₹1,100 Crore
Buyback Record Date	May 29, 2026
Shares to be Bought Back	95,65,217 equity shares

Management Commentary

Dr. Sharvil Patel, Managing Director of Zydus Lifesciences, stated: “We closed FY26 on a strong note, delivering on our commitments — both on revenue growth and profitability. We are confident our pipeline will drive overall growth visibility while future growth engines begin to deliver. Our near-term priorities are clear: maintain consistent quality standards, integrate our recent acquisitions, and capture synergies swiftly. Finally, our strong balance sheet ensures we have the flexibility to invest and strengthen our businesses further.”

Q&A Section — Investors’ Most Asked Questions

Q1. What was Zydus Lifesciences’ net profit in Q4 FY26?

Zydus Lifesciences reported a consolidated net profit of ₹1,273 crore in Q4 FY26, reflecting 8.7% year-on-year growth.

Q2. What was the revenue of Zydus Lifesciences in Q4 FY26?

The company’s revenue from operations stood at ₹7,587 crore in Q4 FY26, up 16% compared to the same quarter last year.

Q3. Did Zydus Lifesciences declare a dividend for FY26?

Yes. The board declared a final dividend of ₹1 per share (100% on face value), with the record date set as July 24, 2026 and payment expected around August 14, 2026.

Q4. What is the Zydus Lifesciences buyback price and size?

The board approved a share buyback at ₹1,150 per share for a total amount of up to ₹1,100 crore. The buyback record date is May 29, 2026.

Q5. Which segment drove the highest growth for Zydus in Q4 FY26?

The Consumer Wellness segment delivered the highest growth at 61% YoY, followed by International Markets Formulations at 45% YoY.

Q6. What was Zydus Lifesciences’ EBITDA margin in Q4 FY26?

EBITDA margin improved to 33.66% in Q4 FY26, compared to 32.56% in Q4 FY25, an improvement of approximately 110 basis points.

Q7. How did Zydus perform in the US market in Q4 FY26?

The North America segment posted revenues of ₹2,952 crore ($323 million in constant currency). While revenue was down 6% annually, it grew 5% sequentially. The company filed 3 ANDAs, received 9 ANDA approvals, and launched 6 new products during the quarter.

Q8. What new products did Zydus launch in India in Q4 FY26?

Zydus launched semaglutide injections (for obesity/diabetes), Tishtha (Nivolumab biosimilar), and Anyra (India’s first indigenously developed Aflibercept biosimilar) during the quarter.

Final Takeaway

Zydus Lifesciences has closed FY26 on a high note — revenue up 17%, EBITDA up 20%, net profit up 9%, and a healthy 31.2% full-year EBITDA margin. The ₹1,100 crore buyback and 100% dividend signal strong management confidence. With a growing biosimilar pipeline, aggressive semaglutide positioning, and expanding international footprint, Zydus looks well-placed to maintain momentum into FY27. Investors should watch for US FDA regulatory updates, margin sustainability, and pipeline commercialization as the next key triggers.

Disclaimer

This blog does not provide financial, investment, or trading advice. All content is for educational and informational purposes only. Please consult a certified financial advisor before making any investment decisions. The author will not be responsible for any financial losses incurred